Kintsugi detects signs of clinical depression and anxiety using machine learning and voice biomarkers.
Kintsugi is developing novel voice biomarker software to detect signs of depression and anxiety from short clips of free form speech. Awarded multiple distinctions for AI technology and recently named one of Forbes’ Top 50 AI companies to watch in 2022, Kintsugi helps to close mental health care gaps across risk-bearing health systems, ultimately saving time and lives.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Feb 28, 2022 | Series A | $20M | 1 | — | — | Detail |
May 17, 2021 | Grant | $1M | 1 | National Science Foundation | — | Detail |
Sep 10, 2020 | Grant | $256K | 1 | National Science Foundation | — | Detail |
Aug 26, 2019 | Grant | $249.77K | 1 | National Science Foundation | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
National Science Foundation | Yes | Grant |
AngelList Talent | — | Series A |